Tumor Infiltrating Lymphocytes Play Prognostic Role in Triple Negative Breast Cancer
the Cancer Therapy Advisor take:
The prognostic role of tumor infiltrating lymphocytes (TIL) has been confirmed in triple negative early breast cancer and there may be a prognostic impact in patients with human epidermal growth factor receptor 2 (HER2)-positive tumors, a new study published online early in the journal Annals of Oncology has shown.
For the study, researchers analyzed data from two multicenter, randomized trials that included 816 patients with breast cancer. Only patients who received adjuvant anthracyclines or no chemotherapy were included in the analysis.
Results showed that Intratumoral TIL and Stromal TIL were strong prognostic factors for overall survival (HR = 0.85; 95% CI: 0.77-0.95; P = 0.003; HR = 0.89; 95% CI: 0.81-0.96; P = 0.005, respectively). Researchers found that the prognostic effect of continuous TIL was limited to patients with triple negative and HER2-positive disease.
The study also showed that TIL should not be used as a parameter to identify patients to receive treatment with anthracyclines.
The prognostic role of tumor infiltrating lymphocytes has been confirmed in triple negative early breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia